Lineage Cell Therapeutics, Inc. (LCTX) Operating cash flow 2016–2025
Lineage Cell Therapeutics, Inc. (LCTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$18.9MFY2025 · since FY2016: -$42.3M → -$18.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$18.9M | +18.1% |
| FY2024 | -$23.1M | +19.2% |
| FY2023 | -$28.6M | -2797.5% |
| FY2022 | $1.1M | +104.5% |
| FY2021 | -$23.6M | -19.3% |
| FY2020 | -$19.8M | +38.2% |
| FY2019 | -$31.9M | -3.4% |
| FY2018 | -$30.9M | -1.2% |
| FY2017 | -$30.5M | +27.9% |
| FY2016 | -$42.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LCTX financial trends
LCTX RevenueLCTX Net incomeLCTX Net marginLCTX Gross profitLCTX Gross marginLCTX Operating incomeLCTX Operating marginLCTX Free cash flowLCTX Capital expendituresLCTX Return on equityLCTX Stock buybacksLCTX Dividends paidLCTX Total assetsLCTX Total liabilitiesLCTX Shareholders’ equityLCTX overview →